Abstract
Respiratory syncytial virus (RSV) is the leading cause of viral lower respiratory tract illness (LRTI) in young children and is associated with significant morbidity, especially among infants, and important burden on health care systems. Nirsevimab is a monoclonal antibody being developed as a passive immunization for the prevention of medically attended RSV-LRTI (RSV MALRTI). Understanding its health economic impact under different scenarios is important to determine the optimal implementation strategy to protect infants entering their first RSV season.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
